BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 6232321)

  • 1. Stabilization of the amplification convertase of complement by monoclonal antibodies directed against human factor B.
    Daha MR; Deelder AM; Van Es LA
    J Immunol; 1984 May; 132(5):2538-42. PubMed ID: 6232321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal anti-human C3d antibodies: stabilization of the alternative pathway C3 convertase.
    Tanuma Y; Ohi H; Hatano M
    Immunology; 1989 Dec; 68(4):445-8. PubMed ID: 2532618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
    Daha MR; Kok DJ; Van Es LA
    Clin Exp Immunol; 1982 Oct; 50(1):209-14. PubMed ID: 6216999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
    Fishelson Z; Müller-Eberhard HJ
    J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
    Waldo FB; Forristal J; Beischel L; West CD
    J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the classical pathway of complement by the C3NeF-stabilized cell-bound amplification convertase.
    Daha MR; van Es LA
    J Immunol; 1979 Mar; 122(3):801-5. PubMed ID: 448075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
    Parker CJ; Baker PJ; Rosse WF
    J Clin Invest; 1982 Feb; 69(2):337-46. PubMed ID: 6915939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C3 nephritic factor protects bound C3bBb from cleavage by factor I and human erythrocytes.
    Mold C; Medof ME
    Mol Immunol; 1985 May; 22(5):507-12. PubMed ID: 3848661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement activation by heat-killed human kidney cells: formation, activity, and stabilization of cell-bound C3 convertases.
    Baker PJ; Adler S; Yang Y; Couser WG
    J Immunol; 1984 Aug; 133(2):877-81. PubMed ID: 6376629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
    Pangburn MK
    J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
    Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
    J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
    Hiramatsu M; Balow JE; Tsokos GC
    J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
    Ng YC; Peters DK
    Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).
    Bexborn F; Andersson PO; Chen H; Nilsson B; Ekdahl KN
    Mol Immunol; 2008 Apr; 45(8):2370-9. PubMed ID: 18096230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H.
    Devine DV; Rosse WF
    Proc Natl Acad Sci U S A; 1987 Aug; 84(16):5873-7. PubMed ID: 2956607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing functional sites on complement protein B with monoclonal antibodies. Evidence for C3b-binding sites on Ba.
    Ueda A; Kearney JF; Roux KH; Volanakis JE
    J Immunol; 1987 Feb; 138(4):1143-9. PubMed ID: 2433342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).
    Seya T; Holers VM; Atkinson JP
    J Immunol; 1985 Oct; 135(4):2661-7. PubMed ID: 3161944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Fearon DT
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.